Transimmune is pioneering the development of immune cell therapies that leverage the natural capabilities of dendritic cells, which have evolved over millions of years. Their approach focuses on creating physiologically-activated dendritic cell products ex vivo, aiming to enhance the immune response in vivo. This innovative strategy is designed to establish a sophisticated partnership with the immune network, potentially improving the efficacy of treatments for various conditions, including cancer and autoimmune diseases. By mimicking the natural processes of dendritic cell production, Transimmune seeks to optimize both the potency of their therapies and the efficiency of the treatment pathway.

The company's pipeline includes products targeting oncology, viral and bacterial infections, and autoimmune diseases, with a focus on developing ex vivo autologous therapies that can be generated rapidly in a point-of-care setting. This method not only aims to enhance the therapeutic impact but also to reduce costs associated with production. Transimmune's commitment to utilizing the inherent complexity of dendritic cells positions them at the forefront of immunotherapy, with the potential to revolutionize how immune responses are harnessed for therapeutic purposes.

Germany

Transimmune AG is leading a revolution in dendritic cell therapy having uncovered how dendritic cells are made physiologically in vivo. 

Transimmune

Company Details